ABOUT THIS PODCAST 🔗

Average audio length:
6 minutes
English
United States
10 episodes
since Aug. 10, 2017
episodic

LATEST EPISODE 🔗

Dr Golfinopoulos meets with ecancertv at IBCD 2016 to discuss SPECTA: a screening platform that sought to encourage patients to participate in clinical trials. He describes how regulatory involvement in trial design and drug design could be streamlined, and the issue of reimbursement for personali…

SEARCH PAST EPISODES

Search past episodes of IBCD 2016.

PREVIOUS EPISODES

Dr Malik speaks with ecancertv at IBCD 2016 to discuss the work of the National Cancer Institute in recruiting patients to clinical trials when subtyping limits disease-wide enrollment. She describes how 'exceptional responders' can be referred to the NCI for genotyping, and schemes to match patie…
Dr Beer speaks with ecancertv at IBCD 2016 about making use of genomic data in a clinically actionable setting. He opens with comments on the work of Dr Moritz Gerstung and considers the issues of storage, access and regulation in genomic libraries. Dr Beer describes how unregulated access and of…
Dr Schneider speaks with ecancertv at IBCD 2016 about the regulatory checkpoints to be passed in the development of assays. He highlights the difference in reproducibility and robustness of research and clinical assays, the clinical utility of validated biomarkers, and how beginning assay developm…
Dr Lacombe speaks with ecancertv at IBCD 2016 about the role of the conference in communicating advances in drug development. He describes the presentations given during a session he chaired at the conference, including the research of Dr Shakun Malik and Dr Vassilis Golfinopoulos. Considering un…
Prof van Dongen speaks with ecancertv at IBCD 2016 about gaining deeper insight into drug action and suitability with radiolabelling. He describes how the journey of radiolabelled ligands may steer drug development, aiming for biomarkers and accumulating in tumours with localised tissue damage and…
Dr Gerstung speaks with ecancertv at IBCD 2016 about genetic analysis of AML patients that has contributed to a predictive model for treatment risk and outcomes. He describes how modelling can be improved with wider data gathering, across populations and tumour types, though this faces the risk of…
Dr Lively joins ecancer at IBCD 2016 to discuss presentations from the conference session she chaired. She discusses the work of Dr Simon Dovedi in developing assays for immune therapy, of Dr Robert Kinders in reproducibility and relevance of assays for clinical trials. Dr Lively reflects on the …
Dr Vietz speaks with ecancertv at IBCD 2016 about the regulatory requirements and quality controls necessary for genomic profiling. She describes her work in constructing consistent, up to date guidelines for genomic assays, and considers balancing cost of access against comprehensive genetic test…
Dr Hewitt speaks with ecancertv at IBCD 2016 about development of assays for predictive biomarkers as a part of personalised therapy. The use of biomarkers he describes could help with the selection of the most effective treatment for patients, depending on gene expression within tumours, and impo…
Disclaimer: The podcast and artwork embedded on this page are from ecancer.org, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.